Ambroxol veterinary-grade API in swine production is handled as a low-dust milled powder with a D90 below 250 µm and a loss on drying below 1.5% by Ph. Eur. 2.2.32. The primary downstream build is a medicated premix for oral administration, manufactured as a 2%–5% w/w ambroxol trituration in lactose monohydrate before further dilution into finished feed. The premix is assembled in a horizontal ribbon mixer with a fill volume of 55%–70% and main shaft speed of 40–60 rpm. To avoid localised pH excursions, the API is first passed through a 500 µm sieve and blended by geometric dilution in 1:1 steps with carrier until the intermediate reaches 5 kg; only then is the remainder of the lactose charged. Blend uniformity at the premix stage is confirmed by Ph. Eur. 2.9.40 with a target recovery of 95%–105% of label claim and an acceptance value not exceeding 15.0. The finished premix is packed in multi-wall paper bags with an inner polyethylene liner; storage above 60% RH causes crusting at the liner surface because the hydrochloride salt picks up water and recrystallises at the interface. Incompatibility is observed with strongly alkaline mineral carriers that push local pH above 7.0, which may precipitate free base and create content non-uniformity; sodium bicarbonate and high-ash mineral mixes above 15% total ash are therefore kept out of the final medicated-feed blend. Carry-over validation is performed under Regulation (EU) 2019/4 Annex II for medicated feed; residual solvent levels are checked against VICH GL18. The terminal finished product is either a 0.5%–2.0% medicated premix for farm-mixed rations or a 5 g oral powder sachet for piglet top-dress application, with the final mg/kg body weight inclusion read from the authorised species-specific SPC. Published data for blend segregation in creep feed when mineral carriers exceed 10% of the total formula is limited.

Does Drinking-Water Alkalinity Above 250 mg/L CaCO₃ Shift the Granule Dissolution Failure Point?

In broiler and turkey drinking-water medication, the first processing conflict appears after the dry granule is reconstituted in line with farm water. Water-soluble granules are produced by top-spray fluid-bed granulation using ambroxol HCl at 10%–20% w/w, povidone K30 as binder at 3%–5% w/w, and a citric acid/sodium citrate buffer pair. The granule is formulated to control reconstituted water pH between 3.5 and 5.0, keeping the molecule ionised and preventing free-base precipitation inside nipple drinker valves. When farm water alkalinity exceeds 250 mg/L CaCO₃, the granule buffer capacity is exhausted before complete dissolution; the resulting free-base haze in the stock solution reduces the effective delivered dose and can block dosing pump filters. The granulation process runs with inlet air at 55–65°C, product temperature at 32–38°C, spray rate of 8–12 g/min/kg batch, and atomising air pressure of 1.5–2.0 bar. Dried granules are sieved through 1.0 mm, with fines below 150 µm recycled into the next batch; laser diffraction under Ph. Eur. 2.9.31 is used to keep d50 between 350 µm and 600 µm. Final water content is controlled below 2.0% by Ph. Eur. 2.2.32. Dissolution is assessed in hard water and in Ph. Eur. 2.9.3 apparatus II at 50 rpm in 900 mL pH 4.5 acetate buffer; the immediate-release criterion of Q ≥ 80% at 30 min applies. The terminal finished product is a water-soluble powder or granule packed in foil-lined sachets, used in poultry drinking-water systems; stock solutions prepared with hard water above 250 mg/L CaCO₃ are pre-softened to avoid visible haze and filter blinding.

Companion Animal Direct-Compression Excipient Compatibility Limits

For companion animal tablets and capsules, direct compression is selected only when the ambroxol hydrochloride particle size and the filler bulk density are locked within narrow boundaries. A D90 below 125 µm and a bulk density between 0.45 g/mL and 0.60 g/mL keep the API distributed during hopper vibration on high-speed presses. Formulations at 10–30 mg per unit use microcrystalline cellulose 102 and lactose monohydrate 200 mesh; sodium starch glycolate 2%–5% w/w; colloidal silicon dioxide 0.5%–1.0% w/w; and magnesium stearate 0.5% w/w. Lubrication time is capped at 3 min; exceeding 5 min shears magnesium stearate onto the API surface and reduces dissolution at 10 min by 10–20% relative to the 3 min baseline. Tablets are compressed on a rotary press at 8–15 kN main compression and 2 kN precompression, giving hardness of 50–80 N and friability below 1.0% under Ph. Eur. 2.9.7. Disintegration is tested by Ph. Eur. 2.9.1 in water at 37°C with a limit of 15 min; dissolution is tested by Ph. Eur. 2.9.3 apparatus II at 50 rpm in 900 mL pH 4.5 buffer, with Q ≥ 80% at 30 min.

Powder flow is controlled through Ph. Eur. 2.9.36; a compressibility index outside 20%–30% triggers a sieve-cut correction rather than an increase of glidant above 1.0%. Capsule filling on a dosator or tamping disc machine uses the same dry blend in capsule size 2 or 3, with fill weight verified at ±5% of target mass and content uniformity measured by Ph. Eur. 2.9.40. Ambroxol HCl has an intense bitter taste; uncoated tablets are therefore film-coated with an immediate-release aqueous hydroxypropyl methylcellulose system at 3%–4% w/w dry polymer weight. The pan coating inlet temperature is held at 60–70°C, outlet at 35–40°C, and atomisation pressure at 1.5–2.0 bar. Storage above 60% RH requires desiccant in packaging and a moisture barrier blister; PVC/PVDC at 250 µm thickness is the minimum for tropical climate zones. The formulation is governed by VICH GL18 for residual solvents and Ph. Eur. 2.2.32 for moisture. The terminal finished product is a scored tablet for dogs or a capsule for small-breed dogs and cats; the final dose must be matched to the authorised veterinary SPC. Published data on feline acceptance of uncoated ambroxol tablets is limited, so coating is not considered optional for cat labels.

Injectable ambroxol hydrochloride solution for cattle and horses carries the strictest pH control of all veterinary dosage forms because ambroxol HCl loses ionised solubility as pH rises. The finished sterile solution is buffered to 4.0–5.5 with citric acid/sodium citrate or acetate; if the pH exceeds 5.5, the risk of particulate formation during cold storage increases. Water for injection is nitrogen-sparged before compounding to keep dissolved oxygen below 2 mg/L. The formulation contains sodium chloride to adjust osmolality to 280–320 mOsmol/kg measured by Ph. Eur. 2.2.35, and disodium edetate at 0.01%–0.02% w/v as a metal-chelating stabiliser. Terminal moist-heat sterilisation at 121°C for 15 min is applied only after stress testing confirms no colour change above Ph. Eur. 2.2.2 reference intensity Y5 at 90°C for 24 h; if degradation products exceed the VICH GL18 residual solvent or VICH GL17 impurity threshold, the product is converted to sterile filtration through a 0.22 µm PVDF or PES membrane into pre-sterilised vials.

Filling lines for 10 mL horse single-dose vials and 50–100 mL cattle multidose vials are blanketed with nitrogen to keep headspace oxygen below 2.0%. Vials are amber type I glass with bromobutyl rubber closures to minimise headspace oxygen ingress. End-product release includes sterility Ph. Eur. 2.6.1, bacterial endotoxins Ph. Eur. 2.6.14 at a limit of 0.5 EU/mg, visible particles Ph. Eur. 2.9.20, and subvisible particles Ph. Eur. 2.9.19. The solution is not to be mixed in the same syringe with alkaline veterinary products; ambroxol free base precipitates rapidly if the pH rises above 5.5 during admixture. Intramuscular formulations may require pH closer to 5.0 to reduce injection-site irritation. The finished product is stored below 25°C and protected from light. Published data for injection-site irritation in cattle at ambroxol concentrations above 1.5% w/v is limited; a new farm-scale formulation must be piloted on a small batch before broader deployment. The terminal product is a sterile solution to match the SPC for intravenous or intramuscular administration.

When Ruminant Top-Dress Powder Is Diluted in High-Fat Carrier Meal, Segregation Risks Increase

Ruminant top-dress powders expose the preparation to the highest shear environment during carrier blending, particularly when soybean hulls or high-fat carrier meal above 5% total fat are used. The hydrophobic carrier surface prevents ambroxol HCl particles from adhering uniformly, causing segregation during augering and a top-dress dose that varies between 70% and 130% of label claim if left uncorrected. The premix is therefore built as an intermediate 5% w/w ambroxol powder on lactose monohydrate or maltodextrin, then diluted in a tumble blender at 20–30 rpm with fill volume at 60%–65%. Both API and carrier are milled or sieved to a particle size ratio between 1:5 and 1:10 before blending. Geometric dilution steps of 1:1 are used until the intermediate reaches 10 kg; the remaining carrier is charged only after the active premix is evenly distributed. Blend uniformity is verified at three sampling points with recovery of 95%–105%; a relative standard deviation above 5% triggers a repeat pass through a conical screw mixer rather than an extended tumble time that would generate fines.

Compliance under Regulation (EU) 2019/4 for medicated feed requires carry-over limits in the mill to be validated; rinsing of the auger and mixer between batches is performed with lactose carrier and the recovered material is destroyed or assigned to a non-food cycle. Finished product is packed in 25 kg paper-antistatic polyethylene bags; at moisture above 60% RH, the product is not emptied into open hoppers for more than 30 min because the powder surface becomes tacky. The top-dress is not to be mixed with alkaline mineral premixes containing zinc oxide and calcium carbonate above 15% of total ash; local pH above 7.0 may reduce dissolution and precipitate free base. Particle size is checked by Ph. Eur. 2.9.31; loss on drying is controlled below 2.0% by Ph. Eur. 2.2.32. The terminal dose must match the SPC for calves, dairy cows, or beef cattle; published data for all age-class transitions in high-fat top-dress carrier systems is limited.

Equine Oral Granules and the pH-Dependent Dissolution Boundary at 40°C

Equine oral granules are wet-granulated onto mannitol rather than lactose because of the lower reducing-sugar risk during storage in hot humid barns. The granulation binder is povidone K30 at 3%–5% w/w; granule water content after fluid-bed drying at inlet 60–65°C and product temperature 35–40°C is below 1.5% by Ph. Eur. 2.2.32. The pH of a 10% aqueous dispersion is held between 3.5 and 5.0; dissolution slows below pH 2.5 in acidified drinking water because the particle surface develops a hydrate layer that retards solvent penetration, although published data for this specific low-pH hydrate effect in equine granules is limited. The granules are filled into 5 g or 10 g sachets under 40% RH; each sachet is heat-sealed to prevent moisture ingress. Dissolution is tested with Ph. Eur. 2.9.3 apparatus II at 50 rpm in 900 mL pH 4.5 buffer at 37°C, with Q ≥ 80% at 30 min. For horses intended for competition, the current FEI Prohibited Substances List must be consulted because ambroxol may have a plasma and urine detection time; withdrawal times must follow national veterinary regulatory advice.

The granule must not be compressed into a bolus without an intermediate disintegrant because the wet-massing strength can exceed 100 N; if a bolus is required, crospovidone at 5%–8% w/w is added before compression. Residual solvent compliance follows VICH GL18; stability is bracketed by VICH GL3 and VICH GL11 for climate zones I and II. The terminal product is an oral granule for mixing into feed; it is not intended for nebulisation. Storage above 30°C may lead to particle softening if the sachet is not kept sealed; opened sachets should be used immediately or discarded because the mannitol matrix absorbs atmospheric moisture and becomes sticky above 60% RH.